Fondaparinux indications and usage: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
No edit summary |
||
| Line 14: | Line 14: | ||
===Treatment of Acute Deep Vein Thrombosis=== | ===Treatment of Acute Deep Vein Thrombosis=== | ||
ARIXTRA is indicated for the treatment of acute [[deep vein thrombosis]] when administered in conjunction with warfarin sodium. | ARIXTRA is indicated for the treatment of acute [[deep vein thrombosis]] when administered in conjunction with [[warfarin ]]sodium. | ||
===Treatment of Acute Pulmonary Embolism=== | ===Treatment of Acute Pulmonary Embolism=== | ||
ARIXTRA is indicated for the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital. | ARIXTRA is indicated for the treatment of acute [[pulmonary embolism]] when administered in conjunction with [[warfarin ]]sodium when initial therapy is administered in the hospital.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f | publisher = | date = | accessdate = }}</ref> | ||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
| Line 24: | Line 23: | ||
{{FDA}} | {{FDA}} | ||
[[Category: Cardiovascular Drugs]] | |||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 20:07, 3 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Indications And Usage
Prophylaxis of Deep Vein Thrombosis
ARIXTRA® is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE):
- In patients undergoing hip fracture surgery, including extended prophylaxis;
- In patients undergoing hip replacement surgery;
- In patients undergoing knee replacement surgery;
- In patients undergoing abdominal surgery who are at risk for thromboembolic complications.
Treatment of Acute Deep Vein Thrombosis
ARIXTRA is indicated for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium.
Treatment of Acute Pulmonary Embolism
ARIXTRA is indicated for the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital.[1]
References
Adapted from the FDA Package Insert.